Mutual funds holding Piramal Pharma shares
64 mutual fund schemes held Piramal Pharma shares in their latest portfolios (October 2026, or September 2026 where a fund house's October 2026 portfolio is not yet in), worth about ₹3,243 cr in all. The largest holders by value are HDFC Flexi Cap Fund (1.4% of the fund), Nippon India Pharma Fund (2.6% of the fund), Franklin India Opportunities Fund (1.6% of the fund).
Against the month before, 1 scheme added Piramal Pharma as a new holding and 2 sold out of it completely.
New holders: Canara Robeco Flexi Cap Fund
Sold out: Franklin India Multi Cap Fund, HDFC Manufacturing Fund
By category: Index Fund (30), Sectoral/Thematic (13), Small Cap (6), Flexi Cap (4), Multi Cap (3), Value / Contra (3).
8 actively managed schemes holding it are rated A+ or A on their track record, among them Bajaj Finserv Flexi Cap Fund, Canara Robeco ELSS - Tax Saver Fund, Helios Flexi Cap Fund, Axis Multicap Fund, LIC MF Small Cap Fund.
Every scheme holding Piramal Pharma, by value
And 24 more schemes with smaller holdings.
Value: the scheme's assets under management × the stock's weight, approximate. Change: the weight against the previous month's portfolio, in percentage points; it moves with the share price as well as with buying and selling. Links go to each scheme's Regular plan.
Common questions
How many mutual funds hold Piramal Pharma shares?
64 schemes held Piramal Pharma in their latest monthly portfolios (October 2026, or September 2026 where a fund house's October 2026 portfolio is not yet in), worth about ₹3,243 cr in all.
Which mutual fund holds the most Piramal Pharma shares?
By value, HDFC Flexi Cap Fund: about ₹1,557 cr, 1.41% of the fund.
Where does this data come from?
From the monthly portfolios that every fund house must publish by the 10th of the following month. Values are approximate: the fund's assets under management multiplied by the stock's weight in the portfolio.
This page lists which funds hold a stock. It is not a view on the stock or a recommendation to buy or sell it or any fund. Ratings describe past track records, not a forecast.
Send us your CAS and get a written report: which of your funds to keep, which to exit and when, where new SIPs should go, and what each change costs in tax.